Fetal and perinatal exposure to drugs and chemicals: Novel biomarkers of risk

Annual Review of Pharmacology and Toxicology

Volumn 54, Issue , 2014, Pages 295-315

  Etwel, Fatma ^a   Hutson, Janine R ^a   Madadi, Parvaz ^a   Gareri, Joey ^a   Koren, Gideon ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Biomarkers; Fetus; Placenta; Risks; Teratology

Indexed keywords

ALCOHOL; BIOLOGICAL MARKER; DRUG CARRIER; ENVIRONMENTAL CHEMICAL; METHYLMERCURY; OPIATE; POLYBROMINATED DIPHENYL ETHER; SEROTONIN UPTAKE INHIBITOR; TERATOGENIC AGENT;

ALCOHOL BLOOD LEVEL; BREAST FEEDING; DRUG SAFETY; DRUG SCREENING; DRUG TRANSPORT; ENVIRONMENTAL EXPOSURE; EX VIVO STUDY; FETUS RISK; HAIR ANALYSIS; HUMAN; MECONIUM; META ANALYSIS (TOPIC); NONHUMAN; PERINATAL PERIOD; PHARMACOGENETICS; PLACENTA; PLACENTA PERFUSION; PREDICTIVE VALUE; PREGNANCY; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PRENATAL EXPOSURE; PRIORITY JOURNAL; PUERPERAL DEPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; TERATOGENICITY; TERATOLOGY; VALIDITY;

BIOLOGICAL MARKERS; BREAST FEEDING; EPIDEMIOLOGIC RESEARCH DESIGN; FEMALE; FETUS; HUMANS; MATERNAL-FETAL RELATIONS; META-ANALYSIS AS TOPIC; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PLACENTA; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RISK FACTORS;

EID: 84891694827     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-011613-135930     Document Type: Review

References (99)

1. Gregg NM. 1941. Congenital cataract following German measles in the mother. Trans. Ophthalmol. Soc. Aust. 3:35-46
2. McBride WG. 1961. Thalidomide and congenital abnormalities. Lancet ii:1358
3. Wilson JG, Brent RL. 1981. Are female sex hormones teratogenic? Am. J. Obstet. Gynecol. 141:567-80
4. Koren G, Pastuszak A, Ito S. 1998. Drugs in pregnancy. N. Engl. J. Med. 338(16):1128-37
5. Ala-Kokko TI, Myllynen P, Vähäkangas K. 2000. Ex vivo perfusion of the human placental cotyledon: implications for anesthetic pharmacology. Int. J. Obstet. Anesth. 9:26-38
6. Miller RK, Wier PJ, Maulik D, di Sant'Agnese PA. 1985. Human placenta in vitro: characterization during 12 h of dual perfusion. Contrib. Gynecol. Obstet. 13:77-84
7. Panigel M, Pascaud M, Brun JL. 1967. Radioangiographic study of circulation in the villi and intervillous space of isolated human placental cotyledon kept viable by perfusion. [In French.] J. Physiol. (Paris) 59:277-84
8. Schneider H, Panigel M, Dancis J. 1972. Transfer across the perfused human placenta of antipyrine, sodium and leucine. Am. J. Obstet. Gynecol. 114:822-28
9. Kraemer J, Klein J, Lubetsky A, Koren G. 2006. Perfusion studies of glyburide transfer across the human placenta: implications for fetal safety. Am. J. Obstet. Gynecol. 195:270-74
10. Ushigome F, Takanaga H, Matsuo H, Yanai S, Tsukimori K, et al. 2000. Human placental transport of vinblastine, vincristine, digoxin and progesterone: contribution of P-glycoprotein. Eur. J. Pharmacol. 408:1-10
11. Ushigome F, Koyabu N, Satoh S, Tsukimori K, Nakano H, et al. 2003. Kinetic analysis of P-glycoproteinmediated transport by using normal human placental brush-bordermembrane vesicles. Pharm. Res. 20:38-44
12. Moretti ME, Rezvani M, Koren G. 2008. Safety of glyburide for gestational diabetes: a meta-analysis of pregnancy outcomes. Ann. Pharmacother. 42:483-90
13. Smit JW, Huisman MT, van Tellingen O, Wiltshire HR, Schinkel AH. 1999. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J. Clin. Investig. 104:1441-47
14. Mölsä M, Heikkinen T, Hakkola J, Hakala K, Wallerman O, et al. 2005. Functional role of P-glycoprotein in the human blood-placental barrier. Clin. Pharmacol. Ther. 78:123-31
15. Langer O, Yogev Y, Xenakis EM, Rosenn B. 2005. Insulin and glyburide therapy: dosage, severity level of gestational diabetes, and pregnancy outcome. Am. J. Obstet. Gynecol. 192:134-39
16. Koren G, ed. 2001. Maternal-Fetal Toxicology: A Clinician's Guide. New York: Marcel Dekker. 3rd ed.
17. Elliott BD, Schenker S, Langer O, Johnson R, Prihoda T. 1994. Comparative placental transport of oral hypoglycemic agents in humans: a model of human placental drug transfer. Am. J. Obstet. Gynecol. 171:653-60
18. Langer O, Conway DL, Berkus MD, Xenakis EM, Gonzales O. 2000. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N. Engl. J. Med. 343: 1134-38
19. Garcia-Bournissen F, Feig DS, Koren G. 2003. Maternal-fetal transport of hypoglycaemic drugs. Clin. Pharmacokinet. 42:303-13
20. Pollex E, Lubetsky AM, Koren G. 2008. The role of placental breast cancer resistance protein in the efflux of glyburide across the human placenta. Placenta 29:743-47
21. Omarini D, Pistotti V, Bonati M. 1992. Placental perfusion. An overview of the literature. J. Pharmacol. Toxicol. Methods 28:61-66
22. Hutson JR, Garcia-Bournissen F, Davis A, Koren G. 2011. The human placental perfusion model: a systematic review and development of a model to predict in vivo transfer of therapeutic drugs. Clin. Pharmacol. Ther. 90:67-76
23. Garland M. 1998. Pharmacology of drug transfer across the placenta. Obstet. Gynecol. Clin. North Am. 25:21-42
24. Hill MD, Abramson FP. 1988. The significance of plasma protein binding on the fetal/maternal distribution of drugs at steady-state. Clin. Pharmacokinet. 14:156-70
25. Kulaga V, Pragst F, Fulga N, Koren G. 2009. Hair analysis of fatty acid ethyl esters in the detection of excessive drinking in the context of fetal alcohol spectrum disorders. Ther. Drug Monit. 31:261-66
26. Sun M, Kingdom J, Baczyk D, Lye SJ, Matthews SG, Gibb W. 2006. Expression of themultidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation. Placenta 27:602-9
27. Curtis PA, McCullough C. 1993. The impact of alcohol and other drugs on the child welfare system. Child Welfare 72:533-42
28. Koren G, Hutson J, Gareri J. 2008. Novel methods for the detection of drug and alcohol exposure during pregnancy: implications for maternal and child health. Clin. Pharmacol. Ther. 83:631-34
29. Jones KL, Smith DW. 1973. Recognition of the fetal alcohol syndrome in early infancy. Lancet 302:999-1001
30. Koren G, Nulman I. 2006. The Motherisk Guide to Diagnosing Fetal Alcohol Spectrum Disorder (FASD). Toronto: Hosp. Sick Child. 2nd ed.
31. Streissguth AP, Bookstein FL, Barr HM, Sampson PD, O'Malley K, Young JK. 2004. Risk factors for adverse life outcomes in fetal alcohol syndrome and fetal alcohol effects. J. Dev. Behav. Pediatr. 25:228-38
32. Refaai MA, Nguyen PN, Steffensen TS, Evans RJ, Cluette-Brown JE, Laposata M. 2002. Liver and adipose tissue fatty acid ethyl esters obtained at autopsy are postmortem markers for premortem ethanol intake. Clin. Chem. 48:77-83
33. Pragst F, Auwaerter V, Sporkert F, Spiegel K. 2001. Analysis of fatty acid ethyl esters in hair as possible markers of chronically elevated alcohol consumption by headspace solid-phase microextraction (HSSPME) and gas chromatography-mass spectrometry (GC-MS). Forensic Sci. Int. 121:76-88
34. Pragst F, Yegles M. 2008. Determination of fatty acid ethyl esters (FAEE) and ethyl glucuronide (EtG) in hair: a promising way for retrospective detection of alcohol abuse during pregnancy? Ther. Drug Monit. 30:255-63
35. Pragst F, Balikova MA. 2006. State of the art in hair analysis for detection of drug and alcohol abuse. Clin. Chim. Acta 370:17-49
36. Wurst FM, Kelso E, Weinmann W, Pragst F, Yegles M, Sundström Poromaa I. 2008. Measurement of direct ethanol metabolites suggests higher rate of alcohol use among pregnant women than found with the AUDIT-a pilot study in a population-based sample of Swedish women. Am. J. Obstet. Gynecol. 198(4):407.e1-5
37. Chan D, Bar-Oz B, Pellerin B, Paciorek C, Klein J, et al. 2003. Population baseline of meconium fatty acid ethyl esters among infants of nondrinking women in Jerusalem and Toronto. Ther. Drug Monit. 25:271-78
38. Brien JF, Chan D, Green CR, Iqbal U, Gareri J, et al. 2006. Chronic prenatal ethanol exposure and increased concentration of fatty acid ethyl esters in meconium of term fetal guinea pig. Ther. Drug Monit. 28:345-50
39. Goh YI, Chudley AE, Clarren SK, Koren G, Orrbine E, et al. 2008. Development of Canadian screening tools for fetal alcohol spectrum disorder. Can. J. Clin. Pharmacol. 15:e344-66
40. Gareri J, Lynn H, Handley M, Rao C, Koren G. 2008. Prevalence of fetal ethanol exposure in a regional population-based sample by meconium analysis of fatty acid ethyl esters. Ther. Drug Monit. 30:239-45
41. Appenzeller BM, Tsatsakis AM. 2012. Hair analysis for biomonitoring of environmental and occupational exposure to organic pollutants: state of the art, critical review and future needs. Toxicol. Lett. 210:119-40
42. Schramm KW. 2008. Hair-biomonitoring of organic pollutants. Chemosphere 72:1103-11
43. D'Havé H, Covaci A, Scheirs J, Schepens P, Verhagen R, DeCoen W. 2005. Hair as an indicator of endogenous tissue levels of brominated flame retardants in mammals. Environ. Sci. Technol. 39:6016-20
44. Aleksa K, Carnevale A, Goodyer C, Koren G. 2012. Detection of polybrominated biphenyl ethers (PBDEs) in pediatric hair as a tool for determining in utero exposure. Forensic Sci. Int. 218:37-43
45. Vähäkangas K, Myllynen P. 2006. Experimental methods to study human transplacental exposure to genotoxic agents. Mutat. Res. 608:129-35
46. Leung AO, Chan JK, Xing GH, Xu Y, Wu SC, et al. 2010. Body burdens of polybrominated diphenyl ethers in childbearing-aged women at an intensive electronic-waste recycling site in China. Environ. Sci. Pollut. Res. Int. 17:1300-13
47. Herbstman JB, Sjödin A, Kurzon M, Lederman SA, Jones RS, et al. 2010. Prenatal exposure to PBDEs and neurodevelopment. Environ. Health Perspect. 118:712-19
48. Harada M. 1995. Minamata disease: methylmercury poisoning in Japan caused by environmental pollution. Crit. Rev. Toxicol. 25:1-24
49. Schoeman K, Bend JR, Hill J, Nash K, Koren G. 2009. Defining a lowest observable adverse effect hair concentrations of mercury for neurodevelopmental effects of prenatal methylmercury exposure through maternal fish consumption: a systematic review. Ther. Drug Monit. 31:670-82
50. Schober SE, Sinks TH, Jones RL, Bolger PM, McDowell M, et al. 2003. Blood mercury levels in US children and women of childbearing age, 1999-2000. JAMA 289:1667-74
51. International Conference On Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). 2005. Detection of toxicity to reproduction for medicinal products & toxicity to male fertility S5(R2). ICH Harmon. Tripart. Guidel., Curr. Step 4 version. http://www.ich.org/ fileadmin/Public-Web-Site/ICH-Products/Guidelines/Safety/S5-R2/Step4/ S5-R2-Guideline.pdf
52. Chambers CD, Johnson DL, Robinson LK, Braddock SR, Xu R, et al. 2010. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum. 62:1494-503
53. Briggs GG, Freeman RK, Yaffe SJ. 2011. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Philadelphia: Wolters Kluwer/LippincottWilliams & Wilkins. 9th ed.
54. Pasternak B, Svanström H, Mølgaard-Nielsen D, Krause TG, et al. 2012. Risk of adverse fetal outcomes following administration of a pandemic influenza A(H1N1) vaccine during pregnancy. JAMA 308:165-74
55. Einarson TR, Leeder JS, Koren G. 1988. A method for meta-analysis of epidemiological studies. Drug Intell. Clin. Pharm. 22:813-24
56. Evans J, Heron J, Francomb H, Oke S, Golding J. 2001. Cohort study of depressedmood during pregnancy and after childbirth. BMJ 323:257-60
57. Cooper WO, Willy ME, Pont SJ, Ray WA. 2007. Increasing use of antidepressants in pregnancy. Am. J. Obstet. Gynecol. 196:544.e1-5
58. Nulman I, Rovet J, Stewart DE, Wolpin J, Gardner HA, et al. 1997. Neurodevelopment of children exposed in utero to antidepressant drugs. N. Engl. J. Med. 336:258-62
59. Koren G, Nordeng H. 2012. Antidepressant use during pregnancy: the benefit-risk ratio. Am. J. Obstet. Gynecol. 207:157-63
60. Bar-Oz B, Einarson T, Einarson A, Boskovic R, O'Brien L, et al. 2007. Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clin. Ther. 29:918-26
61. Minkovitz CS, Strobino D, Scharfstein D, Hou W, Miller T, et al. 2005. Maternal depressive symptoms and children's receipt of health care in the first 3 years of life. Pediatrics 115:306-14
62. Jimenez-Solem E, Andersen JT, Petersen M, Broedbaek K, Jensen JK, et al. 2012. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study. BMJ Open 2(3):e001148
63. Schaefer C, Ornoy A, Clementi M, Meister R, Weber-Schoendorfer C. 2008. Using observational cohort data for studying drug effects on pregnancy outcome-methodological considerations. Reprod. Toxicol. 26:36-41
64. Maguire MJ, Hemming K, Hutton JL, Marson AG. 2008. Overwhelming heterogeneity in systematic reviews of observational anti-epileptic studies. Epilepsy Res. 80:201-12
65. Simunovic N, Sprague S, Bhandari M. 2009. Methodological issues in systematic reviews and metaanalyses of observational studies in orthopaedic research. J. Bone Jt. Surg. Am. 91(Suppl. 3):87-94
66. Koren G. 2007. Medication safety in pregnancy and breastfeeding. In Motherisk Archives of Systematic and Evaluative Reviews, ed. G Koren, pp. 313-603. New York: McGraw-Hill
67. Sequeira-Byron P, Fedorowicz Z, Jagannath VA, Sharif MO. 2011. An AMSTAR assessment of the methodological quality of systematic reviews of oral healthcare interventions published in the Journal of Applied Oral Science (JAOS). J. Appl. Oral Sci. 19:440-47
68. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. 2003. Methodological index for nonrandomized studies (minors): development and validation of a new instrument. ANZ J. Surg. 73:712-16
69. Dolovich LR, Addis A, Vaillancourt JM, Power JD, Koren G, Einarson TR. 1998. Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. BMJ 317:839-43
70. Wikner BN, Stiller CO, Bergman U, Asker C, Källén B. 2007. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. Pharmacoepidemiol. Drug Saf. 16:1203-10
71. Fried S, Kozer E, Nulman I, Einarson TR, Koren G. 2004. Malformation rates in children of women with untreated epilepsy: a meta-analysis. Drug Saf. 27:197-202
72. Veiby G, Daltveit AK, Engelsen BA, Gilhus NE. 2009. Pregnancy, delivery, and outcome for the child in maternal epilepsy. Epilepsia 50:2130-39
73. Nikfar S, Abdollahi M, Moretti ME, Magee LA, Koren G. 2002. Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis. Dig. Dis. Sci. 47:1526-29
74. Pasternak B, Hviid A. 2010. Use of proton-pump inhibitors in early pregnancy and the risk of birth defects. N. Engl. J. Med. 363:2114-23
75. Gill SK, O'Brien L, Koren G. 2009. The safety of histamine 2 (H2) blockers in pregnancy: a meta-analysis. Dig. Dis. Sci. 54:1835-38
76. Matok I, Gorodischer R, Koren G, Sheiner E, Wiznitzer A, et al. 2010. The safety of H2-blockers use during pregnancy. J. Clin. Pharmacol. 50:81-87
77. Walfisch A, Al-maawali A, Moretti ME, Nickel C, Koren G. 2011. Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers. J. Obstet. Gynaecol. 31:465-72
78. Li DK, Yang C, Andrade S, Tavares V, Ferber JR. 2011. Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk ofmalformations in offspring: a retrospective cohort study. BMJ 343:d5931
79. Koren G, Nava-Ocampo AA, Moretti ME, Sussman R, Nulman I. 2006. Major malformations with valproic acid. Can. Fam. Physician 52:441-42
80. Jentink J, Loane MA, Dolk H, Barisic I, Garne E, et al. 2010. Valproic acid monotherapy in pregnancy and major congenital malformations. N. Engl. J. Med. 362:2185-93
81. Banach R, Boskovic R, Einarson T, Koren G. 2010. Long-term developmental outcome of children of women with epilepsy, unexposed or exposed prenatally to antiepileptic drugs: a meta-analysis of cohort studies. Drug Saf. 33:73-79
82. Meador KJ, Baker GA, Browning N, Clayton-Smith J, Combs-Cantrell DT, et al. 2009. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N. Engl. J. Med. 360:1597-605
83. Pastuszak AL, Levy M, Schick B, Zuber C, Feldkamp M, et al. 1994. Outcome after maternal varicella infection in the first 20 weeks of pregnancy. N. Engl. J. Med. 330:901-5
84. Enders G, Miller E, Cradock-Watson J, Bolley I, Ridehalgh M. 1994. Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet 343:1548-51
85. Fuhr U, Jetter A, Kirchheiner J. 2007. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach. Clin. Pharmacol. Ther. 81:270-83
86. Madadi P, Avard D, Koren G. 2012. Pharmacogenetics of opioids for the treatment of acute maternal pain during pregnancy and lactation. Curr. Drug Metab. 13:721-27
87. Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. 2006. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 368:704
88. Madadi P, Shirazi F, Walter FG, Koren G. 2008. Establishing causality of CNS depression in breastfed infants following maternal codeine use. Paediatr. Drugs 10:399-404
89. Madadi P, Ross CJ, Hayden MR, Carleton BC, Gaedigk A, et al. 2009. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin. Pharmacol. Ther. 85:31-35
90. Willmann S, Edginton AN, Coboeken K, Ahr G, Lippert J. 2009. Risk to the breast-fed neonate from codeine treatment to themother: a quantitativemechanistic modeling study. Clin. Pharmacol. Ther. 86:634-43
91. Madadi P, Moretti M, Djokanovic N, Bozzo P, Nulman I, et al. 2008. Guidelines for maternal codeine use during breastfeeding. Can. Fam. Physician 55:1077-78
92. Kelly LE, Chaudhry SA, Rieder MJ, t'Jong G, Moretti ME, et al. 2013. A clinical tool for reducing central nervous system depression among neonates exposed to codeine through breast milk. PLoS ONE 8(7):e70073
93. Way WL, Costley EC, Leongway E. 1965. Respiratory sensitivity of the newborn infant to meperidine and morphine. Clin. Pharmacol. Ther. 6:454-61
94. Rai A, Bhalla S, Rebello SS, Kastrissios H, Gulati A. 2005. Disposition of morphine in plasma and cerebrospinal fluid varies during neonatal development in pigs. J. Pharm. Pharmacol. 57:981-86
95. Bouwmeester NJ, Hop WC, van Dijk M, Anand KJ, van den Anker JN, Tibboel D. 2003. Postoperative pain in the neonate: age-related differences in morphine requirements and metabolism. Intensive Care Med. 29:2009-15
96. Hain RD, Hardcastle A, Pinkerton CR, Aherne GW. 1999. Morphine and morphine-6-glucuronide in the plasma and cerebrospinal fluid of children. Br. J. Clin. Pharmacol. 48:37-42
97. Syvänen S, Xie R, Sahin S, Hammarlund-Udenaes M. 2006. Pharmacokinetic consequences of active drug efflux at the blood-brain barrier. Pharm. Res. 23:705-17
98. Watchko JF, Daood MJ, Mahmood B, Vats K, Hart C, Ahdab-Barmada M. 2001. P-glycoprotein and bilirubin disposition. J. Perinatol. 21(Suppl. 1.):S43-47
99. Daood M, Tsai C, Ahdab-Barmada M, Watchko JF. 2008. ABC transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS. Neuropediatrics 39(4):211-18